Table 1.
Treatment | Cell line (IC50 ± SD) | |||
---|---|---|---|---|
ARMS | ERMS | |||
Rh30 | Rh41 | RD | Rh18 | |
Ceritinib (μM) | 0.50 ± 0.19 | 0.30 ± 0.09 | 0.87 ± 0.02 | 1.0 ± 0.71 |
Dasatinib (μM) | 0.64 ± 0.04 | 6.44 ± 0.43 | 6.88 ± 2.87 | 0.31 ± 0.18 |
ARMS alveolar rhabdomyosarcoma, ERMS embryonal rhabdomyosarcoma, IC50 concentration at which 50% of the cell viability is affected, SD standard deviation